Companies Dominating the Protein Degeneration Therapy Market
- F. Hoffmann-La Roche AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Amgen Inc.
- Baxter International Inc.
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Novo Nordisk A/S
- Pfizer, Inc.
- Sanofi SA
Browse Key Market Insights with Data Illustration:
In the News
- Amgen Inc. teamed up with Generate Biomedicines to identify and develop protein therapies for five targets, help multi-specific drug design even more, and create prospective lead compounds with predictable manufacturability and clinical behavior. In addition, by combining Amgen's biologics drug discovery expertise with Generate's AI platform, they can further shorten drug discovery timelines and could generate over USD 1 billion for the Flagship Pioneering spinout.
- Eli Lilly and Company collaborated with Lycia Therapeutics, Inc. to address critical unmet medical needs in Lilly's therapeutic areas of focus, such as immunology and pain, and use cutting-edge new technology to tackle difficult illness areas such as immunology and pain. Further, this collaboration will enable the development of many therapeutic modalities, including antibodies and small compounds.